Pattern and Clinical Significance of CA19-9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors.

Area of Science:

• Oncology
• Biomarker Research
• Cancer Diagnostics

Background:

• Carbohydrate antigen 19-9 (CA19-9) is a recognized serum marker for pancreatic cancer diagnosis and prognosis.
• Its expression prevalence and clinical significance across diverse human cancers require comprehensive evaluation.

Purpose of the Study:

• To determine the prevalence of CA19-9 expression in a wide array of human tumor types.
• To investigate the clinical relevance and associations of CA19-9 expression with tumor characteristics and patient outcomes.

Main Methods:

• Utilized immunohistochemistry to analyze CA19-9 expression in a large tissue microarray.
• The study included 14,966 tumor samples across 134 types/subtypes and 608 normal tissue samples from 76 types.

Main Results:

• CA19-9 positivity was observed in 79 out of 134 tumor categories, with strong positivity in 66.
• Highest frequencies were in biliopancreatic adenocarcinomas, gastrointestinal adenocarcinomas, testicular embryonal carcinomas, and endometrial carcinomas.
• CA19-9 expression levels correlated with various clinicopathological factors, including tumor stage, metastasis, and genetic mutations, depending on the cancer type.

Conclusions:

• High CA19-9 expression is present in subsets of various cancers, not just pancreatic adenocarcinoma.
• Patients with CA19-9 expressing tumors may benefit from serum monitoring for treatment, recurrence detection, and prognostic prediction.
• Observed associations between CA19-9 levels and aggressive phenotypes align with its complex role in cancer.